SEC Form 10-Q filed by Syndax Pharmaceuticals Inc.
$SNDX
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/24/2024 | $37.00 | Buy | UBS |
| 6/28/2024 | $37.00 | Buy | Jefferies |
| 1/31/2024 | $36.00 → $23.00 | Sector Outperform → Sector Perform | Scotiabank |
| 12/22/2023 | $45.00 | Buy | Mizuho |
| 10/25/2023 | $29.00 | Buy | BofA Securities |
| 10/11/2023 | $30.00 | Buy | Goldman |
| 7/27/2023 | Sector Outperform | Scotiabank | |
| 7/11/2023 | $40.00 | Buy | Guggenheim |
UBS initiated coverage of Syndax Pharmaceuticals with a rating of Buy and set a new price target of $37.00
Jefferies initiated coverage of Syndax Pharmaceuticals with a rating of Buy and set a new price target of $37.00
Scotiabank downgraded Syndax Pharmaceuticals from Sector Outperform to Sector Perform and set a new price target of $23.00 from $36.00 previously
Jefferies analyst Kelly Shi initiates coverage on Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy rating and announces Price Target of $37.
Stifel analyst Bradley Canino maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and raises the price target from $40 to $42.
HC Wainwright & Co. analyst Edward White reiterates Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and maintains $41 price target.
Submission status for SYNDAX PHARMACEUTICALS INC's drug REVUFORJ (ORIG-1) with active ingredient REVUMENIB has changed to 'Approval' on 11/15/2024. Application Category: NDA, Application Number: 218944, Application Classification: Type 1 - New Molecular Entity
– Approval based on positive data from the AUGMENT-101 clinical trial, in which Revuforj delivered robust and durable rates of remission in R/R acute leukemia patients with a KMT2A translocation – – Syndax to host conference call today at 6:00 p.m. ET – WALTHAM, Mass., Nov. 15, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (NASDAQ:SNDX) today announced that the U.S. Food and Drug Administration (FDA) has approved Revuforj® (revumenib) as the first and only menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients one year and older. The FDA previously granted Breakthrough Therap
– Primary endpoint met with CR/CRh rate of 23% in pivotal Ph 2 cohort of R/R mNPM1 AML patients (p-value = 0.0014) – – 47% (30/64) ORR in a heavily pre-treated population, including 75% with prior venetoclax exposure in the efficacy population – – Favorable safety and tolerability profile; only 5% of patients discontinued due to treatment-related adverse events – – Results highlight consistency of revumenib's compelling clinical profile – – sNDA filing in R/R mNPM1 AML expected in 1H25, pending anticipated FDA approval of revumenib in R/R KMT2Ar acute leukemia in 4Q24 – – Syndax to host a conference call today at 8:00 am ET – WALTHAM, Mass., Nov. 12, 2024 /PRNew
– New revumenib and Niktimvo™ clinical data will be highlighted at 66th ASH Annual Meeting – – mNPM1 AML topline data from AUGMENT-101 expected in 4Q24; potential sNDA filing in 1H25 – – Revumenib NDA in R/R KMT2Ar acute leukemia is being reviewed under RTOR; PDUFA action date of December 26, 2024 – – Niktimvo approved by U.S. FDA for treatment of chronic GVHD after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg – – $350 million royalty funding agreement for Niktimvo expected to fund Company through profitability – – Company to host a conference call today at 4:30 p.m. ET – WALTHAM, Mass., Nov. 5, 2024 /PRNewswire/ -- Syndax
4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
3 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
– Approval based on positive data from the AUGMENT-101 clinical trial, in which Revuforj delivered robust and durable rates of remission in R/R acute leukemia patients with a KMT2A translocation – – Syndax to host conference call today at 6:00 p.m. ET – WALTHAM, Mass., Nov. 15, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (NASDAQ:SNDX) today announced that the U.S. Food and Drug Administration (FDA) has approved Revuforj® (revumenib) as the first and only menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients one year and older. The FDA previously granted Breakthrough Therap
USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Nov. 14, 2024 /PRNewswire/ -- USA News Group News Commentary – As many biotech companies within the oncology space begin to roll out their end-of-quarter results, the American Medical Association is pointing out the alarming trend of rising cancer rates, especially with younger people. According to data released from the National Cancer Institute (NCI), a division of the National Institutes of Health (NIH), a map shared by Newsweek showed that the prevalence of cancer varies significantly from state to state. Thankfully, there are plenty of new breakthroughs in the fight against cancer that the World Eco
– Primary endpoint met with CR/CRh rate of 23% in pivotal Ph 2 cohort of R/R mNPM1 AML patients (p-value = 0.0014) – – 47% (30/64) ORR in a heavily pre-treated population, including 75% with prior venetoclax exposure in the efficacy population – – Favorable safety and tolerability profile; only 5% of patients discontinued due to treatment-related adverse events – – Results highlight consistency of revumenib's compelling clinical profile – – sNDA filing in R/R mNPM1 AML expected in 1H25, pending anticipated FDA approval of revumenib in R/R KMT2Ar acute leukemia in 4Q24 – – Syndax to host a conference call today at 8:00 am ET – WALTHAM, Mass., Nov. 12, 2024 /PRNew
8-K - Syndax Pharmaceuticals Inc (0001395937) (Filer)
10-Q - Syndax Pharmaceuticals Inc (0001395937) (Filer)
8-K - Syndax Pharmaceuticals Inc (0001395937) (Filer)
SC 13G/A - Syndax Pharmaceuticals Inc (0001395937) (Subject)
SC 13G/A - Syndax Pharmaceuticals Inc (0001395937) (Subject)
SC 13G - Syndax Pharmaceuticals Inc (0001395937) (Subject)
BOSTON, June 10, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: "PYXS"), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Michael A. Metzger to its Board of Directors, effective June 10, 2024. Mr. Metzger has over 25 years of experience in the biopharmaceutical sector, currently serving as Chief Executive Officer and as a member of the Board of Directors of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) since 2015. "We are delighted to have Michael, a proven leader in our industry with a robust track record of success, join the board," said Lara S. Sullivan, M.D., President and Chief Ex
WALTHAM, Mass., May 15, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (NASDAQ:SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the appointment of Aleksandra Rizo, M.D., Ph.D., to its Board of Directors. Dr. Rizo has extensive clinical development experience and a track record of successfully leading the development of several hematology drugs from discovery through commercialization. She will serve as a member of the Science and Technology Committee of the Board. Dr. Rizo will replace Dr. Briggs Morrison who will step down effective May 14, 2024 after a successful 9-year tenure as a member of the Company's Board of Directo
VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced the appointment of Dr. Neil Gallagher to its board of directors effective April 2, 2024. "Dr. Gallagher is the sixth director to join our board of directors in the past twelve months as we continue to refresh and strengthen the Board governance and oversight required for the next stage of the Company's development and growth," said Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks. "His exp